Introduction
Graves' disease and autoimmune thyroiditis are part of autoimmune thyroid disease (AITD). Although they seem to coexist (1) , the occurrence of Graves' disease after an autoimmune hypothyroidism is particularly outstanding and raises questions about the mechanisms involved. Only a few cases have been reported in the literature (2, 3) .
Case Report
An 18-year-old patient presented to our clinic in 2009 without a history of significant pathology. The diagnosis of autoimmune hypothyroidism was established based on the usual symptoms and a TSH level of 258.20 mIU/l (n=0.27-4.20 mIU/L) and antithyroid peroxidase antibody level of 132.5 IU/ml (n=<30 IU/l). Unexpectedly, the hormone replacement therapy that he received should be reduced in February 2011 due to overdose, and then, gradually stopped in September 2011. While not receiving L-thyroxine, during follow-up, the patient was found to have hyperthyroidism with the following values: TSH: 0.005 mIU/l (n=0.27-4.20 mIU/l), FT3:20.48 pmol/l (n=3.10-6.80 pmol/l) and FT4:44.85 pmol/l (n=12-22 pmol/l). Ultrasonography revealed increased thyroid volume size and echogenicity that was generally hypoechoic. Scintigraphy showed that the contours of the thyroid gland were generally regular and there was no nodule clearly visualized. Ocular examination showed the appearance of exophtalmos. Hertel ophthalmometry confirmed the presence of bilateral exophthalmos. The orbitofrontal cortex was not investigated. Carbimazole treatment was started for Graves' disease based on the presence of anti-TSH receptor antibodies. A year later, while treatment with carbimazole and levothyroxine was continued, biological control showed negativity of antithyroid peroxidase antibodies and a decrease in anti-TSH receptor antibodies. The occurrence of Graves' disease after an autoimmune hypothyroidism is particularly outstanding and raises questions about the mechanisms involved. Here, we report an 18-year-old patient who has been followed up for autoimmune hypothyroidism since 2009. Hormonal biological monitoring has led to gradually reduce the dose of substitution therapy and to stop it in September 2011 due to the occurrence of hyperthyroidism. The diagnosis of Graves' disease was confirmed by the positivity of TSH-receptor antibodies. Carbimazole treatment is then undertaken. This new observation shows that this seemingly paradoxical combination is not impossible and encourages regular surveillance of these patients. Thyroglobulin antibodies are the oldest described but their responsibility in the occurrence of thyroid disease is not engaged and their dosing is not recommended by the National Agency for Accreditation and Evaluation in Health (NAAEH) and the National Academy of Clinical Biochemistry (NACB) (5). Anti-thyroid peroxidase, the main antigen of the thyroid microsomal fraction, plays an important role in inducing cellular cytotoxicity (4). In Graves' disease, anti-thyroid peroxidase and anti-thyroglobulin antibodies are serological markers and not modulators of clinical expression; their positivity reflects the importance of the autoimmune process (6,7). Anti TSH receptor antibodies have a direct pathogenic role; they are present in 90% of cases and are specific to the disease. They belong to several families and their nomenclature is complex: TSH-binding inhibiting antibody (TBIAb) and TSH-binding inhibitor immunoglobulin (TBII) inhibit the binding of TSH to its receptor, thyroid stimulating antibody (TSAb) and thyroid-blocking antibody (TBab) act through the cyclic AMP pathway. Therefore, in this observation, the onset of Graves' disease after autoimmune hypothyroidism can only be explained by the persistence of a strong contingent of functional thyroid cells that may be stimulated by anti TSH receptor antibodies. The joint presence of blocking antibodies and stimulating antibodies reflects the initial silence of Graves' disease. The time to onset of hyperthyroidism is highly variable and ranges from a few months to several years. This type of fluctuation of thyroid function has been reported in a few cases in the literature (2, 8) . Some specific situations such as iatrogenic induction during immunotherapy or allograft, changes in terrain during pregnancy, in genetic diseases or dysimmune disorders and cancers may well be the cause. The clinically overt orbitopathy in this observation is found in about 40% of cases during the diagnosis of Graves' disease (4). Its pathophysiology is still unknown (9) . Anti-TSH receptor antibodies appear to be a determining element based on the notion of a common antigen in the thyroid tissue and orbital tissue: the TSH receptor (10) . Factors contributing to its occurrence may be genetic or environmental, such as smoking, stress, etc.
Discussion

Conclusion
The finding of an autoimmune hypothyroidism usually leads to the final prescription of hormone replacement therapy. The occurrence of Graves' disease during evolution as illustrated in this case is not impossible and justifies regular monitoring.
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